Synchronous isolated splenic metastasis from cancer of hepatic flexure of colon
A case report
Huiying Zhao, MD\textsuperscript{a}, Weixiang Zhong, MD\textsuperscript{b}, Dong Chen, MD\textsuperscript{a}, Xiaofei Cheng, MD\textsuperscript{a,*}

Abstract
Rationale: Isolated splenic metastasis from colorectal cancer is very rare, as metastatic colorectal cancer involving the spleen is usually a manifestation of widely disseminated disease. Splenectomy is the best therapeutic option for this entity and probably the only chance for radical cure.

Patient Concerns: A 73-year-old male presented with abdominal distension and dark red bloody stool of 6-month duration.

Diagnoses: Synchronous isolated splenic metastasis from colorectal cancer.

Interventions: Based on multidisciplinary team (MDT) mode, the patient underwent the primary hepatic flexure tumor resection due to his poor general condition. One month after surgery the patient began treatment with Xelox (capecitabine 1000 mg/m\textsuperscript{2}, oxaliplatin 130 mg/m\textsuperscript{2}) every 3 weeks. The patient underwent isolated splenic metastasis resection successfully by laparoscopic after four courses of chemotherapy.

Outcomes: The patient’s postoperative course was uneventful and he completed four courses of postoperative chemotherapy using the original chemotherapy regimen Xelox (capecitabine 1000 mg/m\textsuperscript{2}, oxaliplatin 130 mg/m\textsuperscript{2}). The patient was subsequently followed up every 3 months and no signs of recurrence were noted in a recent examination.

Lessons: To the best of our knowledge, this is the first case report of isolated splenic metastasis from colorectal cancer in China. It is also the first case in which treatment was overseen by an MDT. The possibility of splenic metastasis should be considered in cases in which colorectal cancer is associated with a splenic lesion, despite its rarity. Splenectomy and adjuvant chemotherapy are the optimal therapeutic approaches, as such an approach prolongs survival and palliates the disease.

Abbreviations: CA 19–9 = cancer antigen 19–9, CEA = carcinoembryonic antigen, CT = computed tomography, MDT = multidisciplinary team.

Keywords: colorectal cancer, isolated splenic metastases, multidisciplinary team, splenectomy

1. Introduction
Isolated splenic metastasis from colorectal cancer is very rare, as metastatic colorectal cancer involving the spleen is usually a manifestation of widely disseminated disease.[1] In a cadaver study, the incidence of splenic metastases from colorectal cancer was 2% of 1019 cases, but the incidence of isolated splenic metastasis was not reported.[2] To the best of our knowledge, only 32 cases (5 synchronous and 27 metachronous cases) of isolated splenic metastasis from colorectal cancer have been reported in the English-language literature.[3] Because synchronous splenic metastasis is very rare, preoperative diagnosis is difficult. Splenectomy is the best therapeutic option for isolated splenic metastasis and probably the only chance for radical cure. Some authors suggest that splenectomy may lead to long-term survival in patients with isolated splenic metastasis.[4,5] Herein, we report the first case of isolated splenic metastasis from colorectal cancer in China. We diagnosed this rare clinical entity and resected the primary tumor and isolated splenic metastasis using a multidisciplinary team (MDT) approach. MDT approach is important for advanced colorectal cancer, especially for patients with synchronous metastasis.[6,7]

2. Case report
In October 2017, a 73-year-old male presented with abdominal distension and dark-red bloody stool of 6-month duration. He
also complained of general fatigue and weight loss of 15 kg. He had no familial history of cancer, no prior pathological conditions, and no concomitant medication use. The patient’s carcinoembryonic antigen (CEA) and hemoglobin levels were 6.9 ng/mL (0–5 ng/mL) and 101 g/L (131–175 g/L), respectively. The results of all other laboratory tests were normal, including cancer antigen 19–9 (CA 19–9), biochemical, and hematologic tests. Endoscopic examination revealed an obstructing neoplasm in the hepatic flexure, about 4.5 cm in diameter, with surface depression, erosion, and a propensity for bleeding. A biopsy of the lesion established a diagnosis of moderately differentiated adenocarcinoma. Whole-abdomen computed tomography (CT) revealed wall thickening of the hepatic flexure with proximal incomplete intestinal obstruction (Fig. 1A). The CT scan also revealed a single low-density lesion of about 5.7 cm in diameter in the spleen (Fig. 1B). Genetic testing of the biopsy material indicated non-mutated KRAS, NRAS, and BRAF genes. After the first MDT discussion, due to the poor general condition of the patient, we decided to remove the primary lesion and biopsy the splenic mass during the operation. The biopsy indicated the presence of splenic metastasis from adenocarcinoma. The patient underwent a laparoscopic right hemicolectomy due to the histopathological finding of a moderately and poorly differentiated adenocarcinoma invading the serosa. Twenty-two lymph nodes were removed and 7 showed metastases (pT3N2M1, stage IV). One month later, the patient’s CEA level had decreased to 3 ng/mL. The patient’s postoperative recovery was uneventful, and 1 month after surgery he began treatment with Xelox (capecitabine 1000 mg/m², oxaliplatin 130 mg/m²) every 3 weeks for 3 months. After 4 courses of Xelox therapy, the patient’s clinical response was excellent, with II degree vomiting and no obvious bone marrow suppression or neurotoxicity. The diameter of the splenic lesion had decreased from 5.7 to 2.5 cm (Fig. 1C), and a partial response had been achieved after 4 courses of chemotherapy. In April 2018, based on a second MDT discussion, the patient underwent laparoscopic splenectomy. The histological findings showed that the splenic tumor was a moderately and poorly differentiated adenocarcinoma, similar to the tumor of the hepatic flexure (Fig. 2A). Negative staining for cytokeratin 7 and positive staining for cytokeratin 20 was consistent with splenic metastasis of an adenocarcinoma of the hepatic flexure (Fig. 2B and C). The patient’s postoperative course was uneventful and he completed 4 courses of postoperative chemotherapy using the original chemotherapy regimen Xelox (capecitabine 1000 mg/m², oxaliplatin 130 mg/ m²). The patient’s clinical response was good, with II degree vomiting, II degree bone marrow suppression, and II degree neurotoxicity. The patient was subsequently followed up every 3 months and no signs of recurrence were noted in a recent examination on January, 2019.

3. Discussion
Approximately 1 in 4 patients with CRC have metastases at the time of initial diagnosis. Metastases to the spleen from colorectal cancer in the absence of liver or lung involvement are extremely rare, possibly due to the anatomical and immunological characteristics of the tumor. The anatomical factors that restrict metastasis include the rhythmic contraction of the sinusoidal splenic architecture and the sharp angle of the splenic artery with the celiac axis. Moreover, immune surveillance in the spleen inhibits tumor cell proliferation. A PubMed search yielded only 32 cases of isolated solitary splenic metastasis from colorectal cancer (synchronous, 5 cases summarized in Table 1; metachronous, 27 cases) in the English language literature. We report here the sixth case in which an isolated splenic lesion was synchronous with colorectal cancer. A particularly interesting aspect of this case is its diagnosis and treatment by an MDT. The MDT is defined as “a group of people of different health-care disciplines, which meets together at a given time to discuss a given patient and who are each able to contribute independently to the diagnostic and treatment decisions about the patients.” The colorectal cancer MDT in our hospital includes colorectal surgeons, hepatobiliary
surgeons, urological surgeons, thoracic surgeons, gynecologists, radiologists, radiation therapist, histopathologists, medical oncologists, and nurse specialists. An MDT approach may not only reduce the risk for perioperative morbidity and mortality but also improves long-term survival.\cite{17,18} None of the cases reported to date were misdiagnosed. Overall, isolated splenic metastasis is relatively easy to diagnose.

Splenectomy is necessary in the presence of isolated metastases from colorectal cancer.\cite{16} Splenectomy was performed in all reported cases of isolated splenic metastasis from colorectal cancer, but only two cases were treated using a laparoscopic approach, as in our patient. Due to the risk for peritoneal dissemination, use of laparoscopy for splenic malignancies is controversial. However, laparoscopic splenectomy for splenic metastasis reportedly does not increase the rate of surgical complications, and survival ranges from 2 months to 11 years.\cite{15} Moreover, laparoscopic surgery for other abdominal tumors is not associated with a greater risk of surgical complications compared to conventional techniques.\cite{20,21} Thus, laparoscopic splenectomy for splenic metastasis is safe and reproducible, and yields outcomes superior to those of open surgery. The survival duration after splenectomy ranges from 3 to 84 months (mean, 22.5 months). Only 2 of 27 reported cases of metachronous splenic metastasis relapsed between 9 and 11 months, compared to 3 of 5 cases of synchronous splenic metastases.\cite{3,22} Chemotherapy is the appropriate treatment for isolated splenic metastases from colorectal cancer, particularly synchronous splenic metastases.\cite{23} Chemotherapy regimens for metastatic colorectal cancer include CapeOX/Xelox (capecitabine 1000mg/m², oxaliplatin 130mg/m²), mFOLFOX6 (5-fluorouracil 2400mg/m², leucovorin 400mg/m², and oxaliplatin 85mg/m²), and FOLFIRI (5-fluorouracil 2400mg/m², leucovorin 400mg/m², and irinotecan 180mg/m²).\cite{18,24,25} Our patient underwent the primary hepatic flexure tumor and isolated splenic metastasis resection in stages due to his poor general condition. The interval between the two operations was about 3 to 4 months. Since this entity was advanced colorectal cancer (pT3N2M1, stage IV), our MDT team recommended that the patient underwent adjuvant chemotherapy first during the waiting period. Our patient completed perioperative chemotherapy using the regimen Xelox (capecitabine 1000mg/m², oxaliplatin 130mg/m²).

In conclusion, we report the first case of isolated splenic metastasis from colorectal cancer in China; it is also the first case in which treatment was overseen by an MDT. Despite its rarity, the possibility of splenic metastasis should be considered in cases in which colorectal cancer is associated with a splenic lesion. Splenectomy and adjuvant chemotherapy is the optimal therapeutic approach; such an approach prolongs survival and palliates the disease. We report this rare clinical entity for the purpose of improving the management and survival of patients with isolated splenic metastases from colorectal cancer.

Acknowledgments

We gratefully acknowledge the contributions made by the clinical nurse specialists, surgeons, radiologists, pathologists, and oncologists to the Colorectal MDT. In particular, we would like to thank: Jianjiang Lin, Wenbin Chen, and Yingsheng Wu.
Table 1
Summary of reported cases of synchronous isolated splenic metastasis from colorectal cancer.

| Case no. | Age, sex  | Primary tumor | CEA (ng/mL) | Size of metastasis (cm) | Treatment | DFI (mo) | Ref. |
|----------|-----------|---------------|-------------|-------------------------|-----------|----------|------|
| 1        | 73, F     | Ascending     | NA          | 1.5–7.5                 | Surgery   | 72       | [13] |
| 2        | 62, M     | Splenic flexure | NA         | 1.5–7.5                 | Surgery   | 24       | [13] |
| 3        | 52, F     | Descending    | 103         | 5                       | Surgery   | 12 relapse | [14] |
| 4        | 49, F     | Ascending     | 36.7        | NA                      | Surgery   | 24 relapse | [15] |
| 5        | 54, F     | Splenic flexure | 31.1        | 4.5                     | Surgery + Cmt | 6 relapse | [16] |
| 6        | 73, M     | Hepatic flexure | 6.9         | 5.7                     | Surgery + Cmt | 6       | Our case |

CEA = carcinoembryonic antigen, Cmt = chemotherapy, DFI = disease-free interval after splenectomy, NA = not available.

Author contributions

Data curation: Huiying Zhao, Weixiang Zhong.
Investigation: Dong Chen.
Visualization: Weixiang Zhong.
Writing – Original Draft: Huiying Zhao.
Writing – Review & Editing: Xiaofei Cheng.

References

[1] Abi Saad GS, Hussein M, El-Saghir NS, et al. Isolated splenic metastasis from colorectal cancer. Int J Clin Oncol 2011;16:306–13.
[2] Berge T. Splenic metastases. Frequencies and patterns. Acta Pathol Microbiol Scand A 1974;82:499–506.
[3] Abdou J, Omor Y, Boutayeb S, et al. Isolated splenic metastasis from colorectal cancer: case report. World J Gastroenterol 2016;22:4610–4.
[4] Takada T, Takami H. Solitary splenic metastasis of a carcinoid tumor of the lung eight years postoperatively. J Surg Oncol 1998;67:47–8.
[5] Lopez Monclova J, Targarona Soler E, Peraza Solis Y, et al. Laparoscopic approach for isolated splenic metastasis: comprehensive literature review and report of 6 cases. Surg Laparosc Endosc Percutan Tech 2013;23:21–4.
[6] Lamb BW, Sevdalis N, Taylor C, et al. Multidisciplinary team working across different tumour types: analysis of a national survey. Ann Oncology 2012;23:1293–300.
[7] Lowes M, Kleiss M, Lueck R, et al. The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer. Int J Colorectal Dis 2017;32:1463–9.
[8] Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982–99.
[9] Klein B, Stein M, Kuten A, et al. Splenomegaly and solitary spleen metastasis in solid tumors. Cancer 1987;60:100–2.
[10] Place RJ. Isolated colon cancer metastasis to the spleen. Am Surg 2001;67:454–7.
[11] Kim JC, Jeong CS, Kim HC, et al. Isolated splenic metastasis from colorectal carcinoma: a case report. J Korean Med Sci 2000;15:355–8.
[12] Gabizon A, Small M, Trainin N. Kinetics of the response of spleen cells from tumor-bearing animals in an in vivo tumor neutralization assay. Int J Cancer 1976;18:813–9.
[13] Ishida H, Konno K, Ishida J, et al. Isolated splenic metastases. J Ultrasound Med 1997;16:743–9.
[14] Avesani EC, Cioffi U, De Simone M, et al. Synchronous isolated splenic metastasis from colon carcinoma. Am J Clin Oncol 2001;24:311–2.
[15] Hiraoka K, Morozumi K, Miyazaki H, et al. Isolated splenic vein thrombosis secondary to splenic metastasis: a case report. World J Gastroenterol 2006;12:6561–3.
[16] Pisani A, Ravarino A, Nieddu R, et al. Synchronous isolated splenic metastasis from colon carcinoma and concomitant splenic abscess: a case report and review of the literature. World J Gastroenterol 2007;13:5516–20.
[17] Lordan JT, Karanjan ND, Quinie N, et al. A 10-year study of outcome following hepatic resection for colorectal liver metastases: the effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol 2009;35:302–6.
[18] Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:386–422.
[19] Gilardi L, Vadrucci M. Isolated metachronous splenic metastasis from colon cancer found by 18F-FDG PET/CT. Clin Nucl Med 2017;42:79–80.
[20] Jingli C, Rong C, Ruoh X. Influence of colorectal laparoscopic surgery on dissemination and seeding of tumor cells. Surg Endosc 2006;20:1759–61.
[21] Zanghi A, Cavallaro A, Piccolo G, et al. Dissemination metastasis after laparoscopic colorectal surgery versus conventional open surgery for colorectal cancer: a metanalysis. Eur Rev Med Pharmacol Sci 2013;17:1174–84.
[22] Pavlovic M, Separovic R, Vukelic-Markovic M, et al. Isolated splenic metastasis from colorectal carcinoma in a high risk patient: a case report. Coll Antropol 2011;35:1307–10.
[23] Cavallaro A, Modugno P, Specchia M, et al. Isolated splenic metastasis from colon cancer. J Exp Clin Cancer Res 2004;23:143–6.
[24] Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv22–40.
[25] Messersmith WA. Systemic management of colorectal cancer. J Natl Compr Canc Netw 2017;15(5S):699–702.